Piramal Pharma has informed that it enclosed disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA Inspection at Digwal facility.
The above information is a part of company’s filings submitted to BSE.